Does Highmark Cover Mounjaro?
The verdict
Conditional on most plans
Highmark (BCBS of Pennsylvania, Delaware, West Virginia, and parts of New York) covers Mounjaro for type 2 diabetes with prior authorization across commercial, ACA, and Medicare Part D lines. Mounjaro is not covered for weight loss. Pennsylvania Medicaid dropped adult weight-loss GLP-1 coverage in 2025; T2D Mounjaro coverage with PA continues. The weight-loss tirzepatide is Zepbound, with separate coverage.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Highmark using your member ID.
Key facts
Pennsylvania Medicaid dropped adult weight-loss GLP-1 coverage in 2025. Mounjaro for type 2 diabetes with PA is still covered; weight-loss tirzepatide (Zepbound) is not.
Pennsylvania Department of Human Services, Medicaid PDL update, 2025
Highmark is a BCBS licensee covering Pennsylvania, Delaware, West Virginia, and parts of New York — one of the largest regional Blues in the country.
Highmark Health plan documentation
The 2026 Medicare Part D out-of-pocket cap is $2,100. Most continuous Mounjaro users for diabetes reach the cap within 2-3 months and pay $0 for the rest of the year.
CMS.gov, Medicare Part D Redesign 2026
Medicare vs. commercial coverage
Whether Highmark covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Highmark Medicare Part D and Medicare Advantage plans cover Mounjaro for type 2 diabetes only — not weight loss — at a specialty or non-preferred tier with prior authorization. The 2026 Part D out-of-pocket cap is $2,100; most continuous users reach it within 2-3 months and pay $0 thereafter. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT in the 2026 Medicare GLP-1 Bridge, which covers weight-loss-approved products only. The Lilly savings card is not usable by Medicare beneficiaries.
Commercial / Employer
Group & marketplace plans
Highmark Commercial/Employer plans cover Mounjaro for type 2 diabetes with prior authorization. Off-label weight-loss use is not covered. ACA/Individual: covered for T2D with PA; weight-loss GLP-1s are commonly excluded. Medicaid (PA/DE/WV): Pennsylvania Medicaid dropped adult weight-loss GLP-1 coverage in 2025; Mounjaro is still covered for T2D with PA. Delaware and West Virginia Medicaid T2D coverage subject to state PDL — verify on your plan. The Lilly savings card ($25/month with coverage; $499/month without) applies to commercially insured patients only, not government programs.
The 5 boxes you must tick to get approved
Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $1,300–$1,560/month retail (WAC ~$1,080). Lilly savings card: $499/month for commercially insured without coverage (max $647/month; up to 13 fills; expires 12/31/2026). Not available to Medicare or Medicaid beneficiaries.
List price with no coverage — before any manufacturer savings card.
With coverage
Commercial with coverage: Lilly savings card as low as $25/month. Medicare Part D: 25% coinsurance after deductible until the $2,100 OOP cap; most continuous users reach the cap in 2-3 months. MFN price $245/month mid-2026 for Medicare. PA/DE/WV Medicaid: nominal cost-share for T2D coverage.
Typical monthly copay once prior authorization is approved.
All figures are estimates; actual cost-share varies by plan tier and pharmacy. Verify on your Highmark plan formulary or member services.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Look up Mounjaro on the Highmark formulary
Visit highmark.com and use the drug search tool for your specific commercial, Medicare, or Medicaid plan. Search for 'Mounjaro' or 'tirzepatide' and confirm it is listed for diabetes (ICD-10 E11.x). Note the tier, prior authorization requirement, and any quantity limits.
- 2
Work with your prescriber on the PA submission
Your prescriber must document your confirmed T2D diagnosis, A1c of 6.5% or higher, and prior use of metformin or a documented contraindication. Submit the prior authorization through your prescriber's office; allow up to 72 hours for standard review.
- 3
Call Highmark member services to confirm coverage and state Medicaid rules
Call the number on the back of your Highmark card. Ask: Is Mounjaro covered for type 2 diabetes on my plan? What is my copay? Is Mounjaro covered for weight loss? (Answer: No — diabetes-only; the weight-loss tirzepatide is Zepbound.) If you are on Medicaid in Pennsylvania, confirm T2D-only coverage given the 2025 adult weight-loss GLP-1 exclusion.
Options if Highmark won't cover Mounjaro
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide)
FDA-approved for type 2 diabetes. Commonly covered on Highmark formularies with prior authorization, often at a preferred or non-preferred brand tier.
Trulicity (dulaglutide)
FDA-approved for T2D. GLP-1 alternative frequently on preferred tiers with lower list price than Mounjaro.
Jardiance (empagliflozin)
SGLT2 inhibitor approved for T2D with cardiovascular benefits. Often covered at preferred tiers on Highmark commercial and Medicaid plans across PA/DE/WV.
Zepbound (tirzepatide) — weight loss only
Same molecule as Mounjaro (tirzepatide) but FDA-approved for chronic weight management — not diabetes. Pennsylvania Medicaid dropped adult weight-loss GLP-1 coverage in 2025, further limiting Zepbound access on Medicaid. Coverage requires a separate weight-loss indication approval.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
No. Highmark does not cover Mounjaro for weight loss under any line of business. Mounjaro is FDA-approved for type 2 diabetes only. Off-label weight-loss requests are denied. For weight loss, the same active ingredient (tirzepatide) is sold as Zepbound, which is FDA-approved for chronic weight management and has its own, often-excluded, coverage. Pennsylvania Medicaid dropped adult weight-loss GLP-1 coverage in 2025.
Yes, for type 2 diabetes. Pennsylvania Medicaid dropped adult weight-loss GLP-1 coverage in 2025 — but T2D coverage for Mounjaro with prior authorization continues. If you are on a Highmark Medicaid plan in Pennsylvania, Mounjaro is covered for a confirmed diabetes diagnosis. Weight-loss use is excluded. Verify on your specific Highmark Medicaid plan or call member services.
Highmark requires a confirmed type 2 diabetes diagnosis (ICD-10 E11.x), A1c of 6.5% or greater, and documented trial or failure of metformin (and often one additional agent). Patient must be 18 or older. Quantity limit is typically 4 pens per 28 days. Your prescriber submits the PA. Verify specific criteria on the Highmark formulary or PA policy.
No. The 2026 Medicare GLP-1 Bridge ($50/month copay, July 1, 2026 – December 31, 2027) covers weight-loss-approved products only — Wegovy, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded because it is FDA-approved for type 2 diabetes, not weight loss. Mounjaro is covered under standard Highmark Part D for diabetes only, subject to the $2,100 annual OOP cap.
Only on a Highmark commercial (employer-sponsored or individual) plan, not Medicare or Medicaid. Commercially insured members with Mounjaro coverage may pay as little as $25/month; without coverage, $499/month (max $647/month; up to 13 fills; expires 12/31/2026). The card is not available to Highmark Medicare Part D, Medicare Advantage, Medicaid, Medigap, DoD, VA, or TRICARE beneficiaries.
Related Articles
Does Blue Cross Blue Shield of Michigan Cover Mounjaro? | Curex
BCBS of Michigan covers Mounjaro for type 2 diabetes with PA, not weight loss. Zepbound weight-loss exclusion upheld by MI DIFS in 2025.
Read moreDoes Blue Cross Blue Shield of Minnesota Cover Mounjaro? 2026 | Curex
BCBS of Minnesota covers Mounjaro for type 2 diabetes with PA — not weight loss. MN Medicaid covers weight-loss GLP-1s for Zepbound, not Mounjaro.
Read moreDoes Blue Cross Blue Shield Cover Mounjaro? 2026 Guide | Curex
BCBS covers Mounjaro for type 2 diabetes with prior authorization — not for weight loss. The weight-loss tirzepatide is Zepbound, with separate coverage.
Read moreDoes Blue Cross Blue Shield of Arizona Cover Mounjaro? | Curex
BCBS of Arizona covers Mounjaro for type 2 diabetes with prior auth — not weight loss. AZ Medicaid covers Wegovy for weight loss, but not Mounjaro.
Read moreDoes Blue Cross Blue Shield of Texas Cover Mounjaro? 2026 | Curex
BCBS of Texas covers Mounjaro for type 2 diabetes with prior auth — not weight loss. The weight-loss tirzepatide is Zepbound, covered separately.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Mounjaro? HCSC 2026 | Curex
BCBS of Illinois (HCSC) covers Mounjaro for type 2 diabetes with PA — not weight loss. IL Medicaid covers T2D but excludes weight-loss GLP-1s.
Read moreInsurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance
Highmark covers Mounjaro for diabetes only, not weight loss, and PA Medicaid dropped adult weight-loss GLP-1s in 2025. For patients who want tirzepatide access without insurance, compounded tirzepatide from $149/mo (and compounded semaglutide from $49/mo) is available at getcurex.com/cl/glp — no insurance required, no prior authorization. This is compounded tirzepatide and is not the same medication as Mounjaro or Zepbound. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Highmark before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.